- Home
- KINS vs EDIT Comparison
KINS vs EDIT Comparison
Compare KINS & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KINS | EDIT |
|---|---|---|
| Founded | 1886 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.0M | 206.0M |
| IPO Year | 2013 | 2016 |
Fundamental Metrics
Financial Performance| Metric | KINS | EDIT |
|---|---|---|
| Price | $14.36 | $2.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.92 |
| AVG Volume (30 Days) | 91.1K | ★ 1.6M |
| Earning Date | 03-05-2026 | 03-09-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | ★ 94.59 | 37.50 |
| EPS | ★ 2.88 | N/A |
| Revenue | ★ $214,867,301.00 | $31,937,000.00 |
| Revenue This Year | $10.53 | N/A |
| Revenue Next Year | $15.00 | N/A |
| P/E Ratio | $5.07 | ★ N/A |
| Revenue Growth | 38.50 | ★ 132.64 |
| 52 Week Low | $13.08 | $0.91 |
| 52 Week High | $22.20 | $4.54 |
Technical Indicators
Market Signals| Indicator | KINS | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 33.55 | 53.26 |
| Support Level | $14.40 | $1.84 |
| Resistance Level | $15.60 | $2.36 |
| Average True Range (ATR) | 0.60 | 0.18 |
| MACD | -0.14 | 0.00 |
| Stochastic Oscillator | 6.61 | 52.91 |
Price Performance
Historical ComparisonAbout KINS Kingstone Companies Inc.
Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.